Pfizer Gets FDA Approval for Bleeding Disorder Treatment
Pfizer Gets FDA Approval for Bleeding Disorder Treatment
MacroGenics shares plunged 77.4% on Friday, erasing $773.2 million in market value, after the biotech reported late Thursday that five patients died in a study of the company’s cancer drug. MacroGenics said two of the deaths were deemed unrelated to the drug, known as vobra duo, according to researchers. “The cause and effect with regard to the drug is still being investigated,” Chief Executive Scott Koenig said of the three deaths on the company's first quarter earnings call on Thursday.
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
Bristol Myers Squibb said its trial evaluating a combination of cancer treatments failed to meet its primary endpoint.
Clobetasol propionate ophthalmic suspension obtained US FDA approval in March 2024.
Assessing the efficacy of Namodenoson versus placebo in 140 MASH patients is the trial’s primary efficacy objective.
The Phase III trial of anito-cel for multiple myeloma is anticipated to begin in late 2024.
Novavax stock popped Friday on news of a licensing deal and minority stake from Big Pharma player Sanofi.
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th
Eli Lilly stock broke out, but then slumped. The FDA is soon to hold a meeting to discuss its Alzheimer's drug. Is LLY stock a buy or a sell?
Interim data surpassed expectations, iTeos said. Elsewhere, Acelyrin revealed chief executive officer Shao-Lee Lin is departing and Bluebird bio gave a fuller account of its gene therapy launches.